TickerGuard
Buy Day today: Poor (57) Mixed market breadth · today: Nonfarm Payrolls (September)
XNCR

Xencor Inc

Healthcare · Biotechnology

24.80$ -0.7% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Xencor Inc (XNCR). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — XNCR
Segment 2023 2024 2025
Reportable Segment $174.6M 100.0% $110.5M 100.0% · -36.7% $125.6M 100.0% · +13.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — XNCR
Segment 2020 2021 2022 2023 2024 2025
Royalties $17.8M 14.5% $80.3M 29.2% · +351.1% $152.1M 92.4% · +89.4% $55.8M 32.0% · -63.3% $67.5M 61.1% · +21.0% $80.3M 63.9% · +18.9%
Milestone $50.2M 40.9% $21.0M 7.6% · -58.2% $5.5M 3.3% · -73.8% $88.5M 50.7% · +1,509.1% $34.5M 31.2% · -61.0% $45.3M 36.1% · +31.3%
Research collaboration $4.5M 3.7% $93.0M 33.8% · +1,966.7% $7.0M 4.3% · -92.5% $30.3M 17.4% · +333.1% $0 0.0% · -100.0% $0 0.0%
Licensing $50.2M 40.9% $80.8M 29.4% · +61.0% $0 0.0% · -100.0% $0 0.0% $8.5M 7.7% $0 0.0% · -100.0%
Non-cash royalties – – $0 0.0% – – –

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?